Company Overview and News

to your dashboard

Headline News

Altum's Antimicrobial Update: SCYNEXIS, Cidara, Matinas

2018-01-10 seekingalpha
We've recently seen SCYNEXIS give us an update on their pipeline and IV formulation. Cidara Therapeutics could give us a crucial catalyst update on their Rezafungin as early as this month. Let's get down to it. While we intended to write up on predicted results from Matinas Biopharma, we were beat in pre-market Monday. (45-0)

ROTY Edition 1 Volume 62: (More) ASH Updates And Trades

2017-12-13 seekingalpha
ASH was a mixed bag for us at ROTY, but I´m glad readers got to see both sides of the coin. (156-1)

ROTY Edition 1 Volume 59: Updates And Trades

2017-12-07 seekingalpha
December had a decidedly rough start for the biotech sector and ROTY, which I discuss below. (102-3)

Cidara Therapeutics: An Attractive Price For A Niche Opportunity With A High Probability Of Success

2017-12-05 seekingalpha
Cidara Therapeutics is an anti-infectives company run by the former management of Trius Therapeutics (acquired by Cubist). (45-0)

Cidara Therapeutics: This ROTY Holding Could Outperform Soon

2017-11-29 seekingalpha
Shares are starting to show signs of technical strength and I expect a significant run-up in December and January. (26-2)

ROTY Edition 1 Volume 56: Cidara Therapeutics In The Spotlight

2017-11-29 seekingalpha
I remind readers of the importance of taking note of selling pressure and reacting according to your plan. (83-1)

Cidara Therapeutics' (CDTX) CEO Jeff Stein on Q3 2017 Results - Earnings Call Transcript

2017-11-11 seekingalpha
Good day, ladies and gentlemen, and welcome to Cidara Therapeutic Third Quarter 2017 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will be given at that time. [Operator Instructions] As a reminder, today's conference may be recorded. (24-0)

ROTY Edition 1 Volume 49: Updates From Quarterly Calls And Trades

2017-11-10 seekingalpha
I remind readers of the need to review quarterly results, filings, and conference calls to monitor changes with their stock holdings. (113-0)

5 Biotech Stocks Well Poised to Surpass Expectations in Q3

2017-11-07 zacks
The Q3 earnings season is approaching its end with 81.2% of the S&P 500 companies having already released results. The majority of players within the medical space have already reported their performance. Per the latest Earnings Trends, total earnings for the medical sector are up 6.5% from the same period last year on 4.6% higher revenues. This year, biotech stocks bounced back strongly after the drug pricing issue affected last year’s performance. (27-0)

What's in the Cards for Merrimack (MACK) in Q3 Earnings?

2017-11-06 zacks
Merrimack Pharmaceuticals, Inc. (MACK - Free Report) is expected to report third-quarter 2017 results around Nov 8, before market opens. Last quarter, Merrimack missed bottom-line expectations by 57.14%. (85-0)

What's in the Cards for Repros (RPRX) This Earnings Season?

2017-11-06 zacks
Repros Therapeutics Inc.  is expected to report third-quarter 2017 results around Nov 14. Let’s see how things are shaping up for this quarter. (96-0)

T2 Biosystems' (TTOO) CEO John McDonough on Q3 2017 Results - Earnings Call Transcript

2017-11-03 seekingalpha
Greetings, and welcome to the T2 Biosystems' Third Quarter 2017 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (24-1)

CDTX / Cidara Therapeutics, Inc. - Stock Institutional Ownership and Shareholders -

Cidara Therapeutics, Inc. (NASDAQ:CDTX) has 55 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 13,217,456 shares. Largest shareholders include Bb Biotech Ag, FMR LLC / Fidelity Management & Research, Interwest Venture Management Co, Frazier Management Llc, and Aisling Capital LLC. (8-1)

ROTY Volume 1 Edition 42: Thoughts On Underpeformers And New Trades

2017-10-24 seekingalpha
We are also swapping a Contender for a current ROTY holding due to higher perceived upside and an important near term catalyst. (132-6)

CUSIP: 171757107